New Publication from Rwanda about HCV therapy experience

Hepatitis C treatment outcomes using Interferon- and Ribavirin-based therapy in Kigali, Rwanda. By Riedel DJ et al in Trans R Soc Trop Med Hyg. 2016 Sep 12. Abstract BACKGROUND: Hepatitis C virus (HCV) treatment data in sub-Saharan Africa are limited. This study was to determine HCV sustained virologic response(SVR) at…

Read More

FDA Approves Gilead’s HIV Tablet Odefsey, an Updated Version of Complera

March 1, 2016 The U.S. Food and Drug Administration (FDA) has approved the single-tablet HIV treatment regimen Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide), which includes a new, safer version of tenofovir. Pronounced “oh-DEF-see,” the tablet is an updated version of Complera (rilpivirine/tenofovir disoproxil fumarate/emtricitabine), swapping tenofovir alafenamide, or TAF, for tenofovir disoproxil fumarate,…

Read More

The Eighth Annual Conference and Workshop for Gastrointestinal and Liver Diseases for Especialized Centers of Middle Euphrates Governorates and IMI

It is our pleasure to invite you to “The Eighth Annual Conference and Workshop for Gastrointestinal and Liver Diseases for Especialized Centers of Middle Euphrates Governorates and IMI” to be held in Karbal/Iraq from Wednesday, March 16, 2016_ Friday 18, 2016 at the main conference hall, Imam Hussain Medical City.…

Read More